PDF(Pubmed)
Abstract：
UNASSIGNED: The efficacy of uncovered self-expandable metal stents (UCSEMS) versus fully covered self-expandable metal stents for distal malignant biliary obstruction remains controversial. Additionally, the heterogeneity of the disease conditions has been indicated in previous studies because pancreatic and non-pancreatic cancers have different characteristics in clinical course. Therefore, the etiology of biliary obstruction necessitates investigations stratified by primary disease. This study aimed to evaluate the outcomes of UCSEMS, specifically for non-pancreatic cancer-induced distal malignant biliary obstruction.
UNASSIGNED: We conducted a single-center retrospective review to evaluate the time to recurrent biliary obstruction and frequency of adverse events (AEs) in patients receiving UCSEMS for unresectable non-pancreatic cancer-induced malignant biliary obstruction.
UNASSIGNED: Overall, 32 patients were enrolled in the study between January 2016 and December 2023. The median time to recurrent biliary obstruction was 140 days. AE rates were low at 3.1% for both pancreatitis and cholecystitis, suggesting a potential benefit of UCSEMS in reducing post-procedural AEs.
UNASSIGNED: UCSEMS may reduce the risk of post-procedural AEs and should be considered in patients at high risk of post-endoscopic retrograde cholangiopancreatography pancreatitis. However, the patency period may be shorter, necessitating future comparative research with fully covered self-expandable metal stents to determine the optimal stent choice.
UNASSIGNED: We conducted a single-center retrospective review to evaluate the time to recurrent biliary obstruction and frequency of adverse events (AEs) in patients receiving UCSEMS for unresectable non-pancreatic cancer-induced malignant biliary obstruction.
UNASSIGNED: Overall, 32 patients were enrolled in the study between January 2016 and December 2023. The median time to recurrent biliary obstruction was 140 days. AE rates were low at 3.1% for both pancreatitis and cholecystitis, suggesting a potential benefit of UCSEMS in reducing post-procedural AEs.
UNASSIGNED: UCSEMS may reduce the risk of post-procedural AEs and should be considered in patients at high risk of post-endoscopic retrograde cholangiopancreatography pancreatitis. However, the patency period may be shorter, necessitating future comparative research with fully covered self-expandable metal stents to determine the optimal stent choice.
摘要：
■未覆盖的自膨胀金属支架（UCSEMS）与完全覆盖的自膨胀金属支架治疗远端恶性胆道梗阻的疗效仍存在争议。此外,由于胰腺癌和非胰腺癌在临床过程中具有不同的特征，因此先前的研究已经表明了疾病状况的异质性。因此,胆道梗阻的病因需要按原发疾病进行分层研究。本研究旨在评估UCSEMS的结果，特别适用于非胰腺癌引起的远端恶性胆道梗阻。
■我们进行了一项单中心回顾性研究，以评估接受UCSEMS治疗不可切除的非胰腺癌引起的恶性胆道梗阻的患者复发胆道梗阻的时间和不良事件(AE)的频率。
■总的来说，在2016年1月至2023年12月期间，32名患者被纳入研究。胆道梗阻复发的中位时间为140天。胰腺炎和胆囊炎的AE发生率均较低，为3.1％，表明UCSEMS在减少术后AE方面的潜在益处。
■UCSEMS可降低术后AE的风险，对于内镜逆行胰胆管造影术后胰腺炎高危患者应考虑。然而,通畅期可能会更短，需要进行完全覆盖的自膨胀金属支架的未来比较研究，以确定最佳的支架选择。
■我们进行了一项单中心回顾性研究，以评估接受UCSEMS治疗不可切除的非胰腺癌引起的恶性胆道梗阻的患者复发胆道梗阻的时间和不良事件(AE)的频率。
■总的来说，在2016年1月至2023年12月期间，32名患者被纳入研究。胆道梗阻复发的中位时间为140天。胰腺炎和胆囊炎的AE发生率均较低，为3.1％，表明UCSEMS在减少术后AE方面的潜在益处。
■UCSEMS可降低术后AE的风险，对于内镜逆行胰胆管造影术后胰腺炎高危患者应考虑。然而,通畅期可能会更短，需要进行完全覆盖的自膨胀金属支架的未来比较研究，以确定最佳的支架选择。
